Details for New Drug Application (NDA): 214753
The generic ingredient in SIROLIMUS is sirolimus. There is one drug master file entry for this compound. Twenty suppliers are listed for this compound. Additional details are available on the sirolimus profile page.
Summary for 214753
| Tradename: | SIROLIMUS |
| Applicant: | Alkem Labs Ltd |
| Ingredient: | sirolimus |
| Patents: | 0 |
Pharmacology for NDA: 214753
| Mechanism of Action | Protein Kinase Inhibitors mTOR Inhibitors |
| Physiological Effect | Decreased Immunologic Activity |
Medical Subject Heading (MeSH) Categories for 214753
Suppliers and Packaging for NDA: 214753
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SIROLIMUS | sirolimus | TABLET;ORAL | 214753 | ANDA | Major Pharmaceuticals | 0904-7248 | 0904-7248-04 | 30 BLISTER PACK in 1 CARTON (0904-7248-04) / 1 TABLET, FILM COATED in 1 BLISTER PACK |
| SIROLIMUS | sirolimus | TABLET;ORAL | 214753 | ANDA | Ascend Laboratories, LLC | 67877-746 | 67877-746-01 | 100 TABLET, FILM COATED in 1 BOTTLE (67877-746-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.5MG | ||||
| Approval Date: | Mar 12, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
| Approval Date: | Mar 12, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2MG | ||||
| Approval Date: | Mar 12, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
